🇺🇸 FDA

Intelligence · Clinical Pipeline

Neurology & CNS · Phase III

Neurology & CNS programs at Phase III — ClinicalTrials.gov pipeline intelligence.

Programs
212

Quick answer

Neurology & CNS Phase III programs: NovaPharmaNews indexes 212 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 3 of 5

  1. Low Frequency Right sided repetitive transcranial magnetic stimulation (LFR rTMS)

    United Therapeutics Europe Ltd

    TBI Depression

    phase 3 other completed

    1 trial

  2. Lu AF35700

    H. Lundbeck A/S

    Treatment-resistant Schizophrenia

    phase 3 small molecule terminated

    1 trial

  3. Lurasidone

    Sumitomo Pharma (Suzhou) Co.,

    Bipolar I Depression

    phase 3 small molecule completed

    1 trial

  4. Matched placebo for product, Frexalimab

    Sanofi-aventis Healthcare Pty Ltd

    Multiple sclerosis

    phase 3 small molecule active

    1 trial

  5. Medical Air, KALINOX 50%/50%, gaz médicinal comprimé

    Tour Hekla

    Resistant Depression in the Elderly Subject

    phase 3 small molecule active

    1 trial

  6. Methylprednisolon acis 250 mg Pulver und Lösungsmittel zur Herstellung einer Injektions- bzw. Infusionslösung, Ocrevus 300 mg concentrate for solution for infusion, Gilenya 0.25 mg hard capsules, Placebo for FINGOLIMOD, Placebo for Ocrelizumab, Gilenya 0.25 mg hard capsules, Reisetabletten AL Dimenhydrinat 50 mg pro Tablette, Methylprednisolon acis 1000 mg Pulver und Lösungsmittel zur Herstellung einer Injektions- bzw. Infusionslösung, Gilenya 0.5 mg hard capsules, Gilenya 0.25 mg hard capsules

    Hoffmann-La Roche

    Relapsing-Remitting Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  7. Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, Paracetamol Accord 1000 mg comprimate efervescente, Diphenhydramine Hydrochloride Tablets 50 mg

    Hoffmann-La Roche

    Progressive multiple sclerosis (PMS)

    phase 3 small molecule active

    1 trial

  8. Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion, Paracetamol Accord 1000 mg comprimate efervescente, Ocrevus 300 mg concentrate for solution for infusion, Diphenhydramine Hydrochloride Tablets 50 mg

    Hoffmann-La Roche

    Multiple sclerosis (MS)

    phase 3 small molecule active

    1 trial

  9. NBI-1117568

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 3 small molecule active

    5 trials

  10. NBI-1117568, NBI-1117568

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia, Schizophrenia

    phase 3 small molecule active

    1 trial

  11. NBI-1117568, NBI-1117568, NBI-1117568 Placebo Capsule

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 3 small molecule active

    1 trial

  12. Nabilone

    BRIGHT MINDS BIOSCIENCES INC.

    Alzheimer Disease

    phase 3 small molecule active

    1 trial

  13. Nabiximols

    Jazz Pharmaceuticals Ireland Limited

    Multiple Sclerosis (MS)

    phase 3 small molecule terminated

    1 trial

  14. Nabiximols

    Jazz Pharmaceuticals Ireland Limited

    Spasticity in Participants With Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  15. Nabiximols

    Jazz Pharmaceuticals Ireland Limited

    Spasticity With Multiple Sclerosis

    phase 3 small molecule terminated

    1 trial

  16. OCRELIZUMAB, LOU064, OCRELIZUMAB

    Novartis Pharmaceuticals

    Relapsing multiple sclerosis

    phase 3 small molecule active

    1 trial

  17. Ocrelizumab

    Hoffmann-La Roche

    Multiple Sclerosis, Primary Progressive

    phase 3 small molecule active

    1 trial

  18. Ocrelizumab IV

    Hoffmann-La Roche

    Relapsing Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  19. Ocrelizumab, -, METHYLPREDNISOLONE , DEXAMETHASONE , Ocrevus, -

    Hoffmann-La Roche

    Neurological Disease

    phase 3 small molecule active

    1 trial

  20. Ocrevus 300 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 3 small molecule active

    1 trial

  21. Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 920 mg solution for injection

    Hoffmann-La Roche

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  22. Ocrevus 300 mg concentrate for solution for infusion, Paracetamol 500mg Tablets, Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Placebo ocrelizumab, Diphenhydramine Hydrochloride Tablets 50 mg, Ocrevus 300 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Relapsing Multiple Sclerosis (MS)

    phase 3 small molecule active

    1 trial

  23. Ocrevus, ABP 692, Ocrevus 300 mg concentrate for solution for infusion

    Amgen

    Relapsing-remitting Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  24. Ocrevus, Ocrevus 300 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 3 small molecule active

    1 trial

  25. Orelabrutinib

    Zenas BioPharma

    Multiple Sclerosis (MS) Primary Progressive

    phase 3 small molecule active

    1 trial

  26. Orelabrutinib

    Zenas BioPharma

    Secondary Progressive Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  27. Orelabrutinib, Placebo tablets match with that of orelabrutinib (ICP-022) tablets in appearance, shape, size, and weight.

    Zenas BioPharma

    Primary Progressive Multiple Sclerosis (PPMS)

    phase 3 small molecule active

    1 trial

  28. Oxcarbazepine XR

    SUPERNUS PHARMACEUTICALS, INC.

    Partial Epilepsy

    phase 3 small molecule completed

    1 trial

  29. Ozanimod HCl, Ozanimod HCl, FINGOLIMOD, Ozanimod HCl, Ozanimod HCl, FINGOLIMOD, Ozanimod HCl 0.23 mg , Ozanimod HCl 1 mg , Ozanimod HCl 0.0575 mg , Ozanimod HCl 0.25 mg, Fingolimod 0.25 mg capsule, Fingolimod 0.5 mg capsule

    Bristol-Myers Squibb Australia Pty Ltd

    Relapsing Remitting Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  30. Ozempic 1 mg solution for injection in pre-filled pen, Semaglutide Placebo, Ozempic 0.5 mg solution for injection in pre-filled pen, Ozempic 0.25 mg solution for injection in pre-filled pen

    NovoThirteen

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

  31. PRAX-628, PRAX-628, Placebo for PRAX-628, PRAX-628

    Chongqing Precision Biotech Co., Ltd

    Focal Epilepsy

    phase 3 small molecule active

    1 trial

  32. Paliperidone palmitate

    Janssen Cilag International NV

    Schizophrenia

    phase 3 small molecule completed

    2 trials

  33. Phase 1: Olanzapine

    Shanghai Mental Health Center

    Schizophrenia

    phase 3 small molecule completed

    1 trial

  34. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Schizophrenia

    phase 3 small molecule completed

    4 trials

  35. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Neuropsychiatric Symptoms Related to Neurodegenerative Disease

    phase 3 small molecule completed

    2 trials

  36. Pimavanserin tartrate (ACP-103)

    Acadia Pharmaceuticals B.V.

    Parkinson's Disease Psychosis

    phase 3 small molecule completed

    4 trials

  37. Pioglitazone

    Takeda

    Mild Cognitive Impairment Due to Alzheimer's Disease

    phase 3 small molecule terminated

    2 trials

  38. Placebo

    Biogen

    Multiple Sclerosis, Remittent Progressive

    phase 3 small molecule completed

    1 trial

  39. Placebo

    Jazz Pharmaceuticals Ireland Limited

    Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  40. Placebo

    Blackmores Limited

    Parkinsons Disease (PD)

    phase 3 small molecule active

    1 trial

  41. Placebo

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 3 small molecule completed

    2 trials

  42. Placebo

    SUPERNUS PHARMACEUTICALS, INC.

    Postpartum Depression

    phase 3 small molecule completed

    2 trials

  43. Placebo

    SUPERNUS PHARMACEUTICALS, INC.

    Epilepsies, Partial

    phase 3 small molecule completed

    1 trial

  44. Placebo

    Sumitomo Pharma (Suzhou) Co.,

    Bipolar Depression

    phase 3 small molecule completed

    1 trial

  45. Placebo

    Hoffmann-La Roche

    Schizophrenia

    phase 3 small molecule completed

    1 trial

  46. Placebo Ocrelizumab, Paracetamol 500mg Tablets, Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, Diphenhydramine Hydrochloride Tablets 50 mg

    Hoffmann-La Roche

    Primary Progressive Multiple Sclerosis (PPMS)

    phase 3 small molecule active

    1 trial

  47. Placebo Ocrevus, DIPHENHYDRAMINE HYDROCHLORIDE, METHYLPREDNISOLONE , METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE, Ocrevus 300 mg concentrate for solution for infusion, METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE, Dormutil N, Ocrevus 300 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Primary progressive multiple sclerosis (PPMS)

    phase 3 small molecule active

    1 trial

  48. Placebo Trontinemab, Amyvid 800 MBq/mL solution for injection, VIZAMYL 400 MBq/mL solution for injection, Amyvid 1900 MBq/mL solution for injection, Amyvid 1900 MBq/mL solution for injection, Amyvid 800 MBq/mL solution for injection, Neuraceq 300 MBq/mL solution for injection, Trontinemab, [18F]MK-6240

    Hoffmann-La Roche

    Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD)

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many neurology & cns Phase III programs exist?

212 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.